NCT Number: NCT07364058
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Brussels, 1200, Belgium
Christophe Beauloye, Medical Degree
PRINCIPAL_INVESTIGATOR
Louis Charki, Medical Degree
CONTACT
Louis Charki, Medical Degree
SUB_INVESTIGATOR
Maxime Elens, Medical Degree
SUB_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tissue sample and data collection
Time frame: Throughout the entire study, approximately during 3 years
The number of cells/area expressing the GARP protein will be assessed
Time frame: Throughout the entire study, approximately during 3 years
The number of cells expressing GARP will be assessed as a number of cells / area
Time frame: Throughout the entire study, approximately during 3 years
The type of cells expressing GARP will be assessed as a number of cells / area
Contact information is provided by the study sponsor or research team.
Université Catholique de Louvain
Other
Acronym: CAPGAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04470687
Arterial Occlusive Diseases, Atheroma; Carotid Artery
Paris, France
View Trial DetailsNCT06541691
Arterial Occlusive Diseases, Arteriosclerosis
Tehran, Tehran Province, Iran
View Trial DetailsNCT00715273
Arterial Occlusive Diseases, Arteriosclerosis
Los Angeles, California, United States
View Trial DetailsNCT01178320
Arterial Occlusive Diseases, Arteriosclerosis
Phoenix, Arizona, United States
View Trial Details